XNYS · Healthcare · Diagnostics & Research
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | 2.31 | 2.70 | +16.88% | $1.27B | ✅ Beat | +3.02% | +2.76% | — |
| 2026-02-09 | Q4 2025 | 4.51 | 4.53 | +0.44% | $932.4M | ✅ Beat | -2.12% | -2.04% | -9.33% |
| 2025-11-04 |
| Q3 2025 |
| 3.21 |
| 3.40 |
| +5.92% |
| $799.9M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-04 | Q2 2025 | 2.94 | 2.95 | +0.34% | $771.3M | ✅ Beat | — | — | — |
| 2025-02-12 | Q4 2024 | 4.03 | 4.10 | +1.74% | $872.7M | ✅ Beat | -0.73% | -1.03% | -1.25% |
| 2024-11-01 | Q3 2024 | 2.68 | 2.93 | +9.33% | $740.3M | ✅ Beat | +0.03% | -0.70% | -0.03% |
| 2024-07-31 | Q2 2024 | 2.56 | 2.63 | +2.73% | $708.5M | ✅ Beat | +4.83% | -4.29% | +2.99% |
| 2024-05-07 | Q1 2024 | 2.10 | 2.21 | +5.24% | $636.8M | ✅ Beat | -0.69% | +10.10% | -7.82% |
Showing last 8 quarters.